CSIMarket
 


Revance Therapeutics Inc   (RVNC)
Other Ticker:  
 
 

Revance Therapeutics Inc Net Income per Employee

RVNC's Quarterly Results, Trends, Rankings, Statistics

Revance Therapeutics Inc recorded a cumulative net loss of $0 million during 12 month ending in the forth quarter 2023.
The Healthcare sector has seen employees of 31 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 1369, from total ranking in previous quarter at 1456.


What is Income per Employee Ratio?





RVNC Net Income per Employee (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Net Income Change 1.06 % - - - -
Net Income per Employee (TTM) $ -862 -4,695 -5,845 11,060 -2,011
RVNC's Total Ranking # 1369 # 1456 # 2074 # 1604 # 0
Seq. Net Income Change - - - - -


RVNC Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 105
Overall Market # 1369

Net Income per Employee Statistics
High Average Low
$ 11,060 $ -431,558 $ -1,616,724
(Mar 31 2023)   (Dec 31 2021)







Companies with similar Income per Employee for 12 month ending Dec 31 2023, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2023Number of Employees Dec 31 2023


Date modified: 2024-02-29T16:57:27+00:00




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com